These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
235 related articles for article (PubMed ID: 29295870)
1. Effect of liraglutide on atrial natriuretic peptide, adrenomedullin, and copeptin in PCOS. Frøssing S; Nylander M; Kistorp C; Skouby SO; Faber J Endocr Connect; 2018 Jan; 7(1):115-123. PubMed ID: 29295870 [TBL] [Abstract][Full Text] [Related]
2. Atrial natriuretic peptide, copeptin and adrenomedullin levels in polycystic ovary syndrome: a case-control study. Frøssing S; Nylander M; Aziz M; Skouby SO; Kistorp C; Faber J Gynecol Endocrinol; 2017 Jan; 33(1):30-33. PubMed ID: 27424881 [TBL] [Abstract][Full Text] [Related]
3. The impact of the glucagon-like peptide-1 receptor agonist liraglutide on natriuretic peptides in heart failure patients with reduced ejection fraction with and without type 2 diabetes. Nielsen R; Jorsal A; Tougaard RS; Rasmussen JJ; Schou M; Videbaek L; Gustafsson I; Faber J; Flyvbjerg A; Wiggers H; Tarnow L; Kistorp C Diabetes Obes Metab; 2020 Nov; 22(11):2141-2150. PubMed ID: 32627271 [TBL] [Abstract][Full Text] [Related]
4. Associations of cardiac stress biomarkers with incident type 2 diabetes and changes in glucose metabolism: KORA F4/FF4 study. Sujana C; Seissler J; Jordan J; Rathmann W; Koenig W; Roden M; Mansmann U; Herder C; Peters A; Thorand B; Then C Cardiovasc Diabetol; 2020 Oct; 19(1):178. PubMed ID: 33066780 [TBL] [Abstract][Full Text] [Related]
5. Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial. von Scholten BJ; Persson F; Rosenlund S; Eugen-Olsen J; Pielak T; Faber J; Hansen TW; Rossing P Diabetes Obes Metab; 2017 Jun; 19(6):901-905. PubMed ID: 28105731 [TBL] [Abstract][Full Text] [Related]
6. Short-Term Influence of Radiofrequency Ablation on NT-proBNP, MR-proANP, Copeptin, and MR-proADM in Patients With Atrial Fibrillation: Data From the Observational SMURF Study. Charitakis E; Walfridsson H; Alehagen U J Am Heart Assoc; 2016 Sep; 5(9):. PubMed ID: 27633393 [TBL] [Abstract][Full Text] [Related]
7. Prognostic performance of multiple biomarkers in patients with non-ST-segment elevation acute coronary syndrome: analysis from the MERLIN-TIMI 36 trial (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis In Myocardial Infarction 36). O'Malley RG; Bonaca MP; Scirica BM; Murphy SA; Jarolim P; Sabatine MS; Braunwald E; Morrow DA J Am Coll Cardiol; 2014 Apr; 63(16):1644-53. PubMed ID: 24530676 [TBL] [Abstract][Full Text] [Related]
8. Copeptin and MR-proADM in umbilical cord plasma reflect perinatal stress in neonates born to mothers with diabetes and MR-proANP reflects maternal diabetes. Smith J; Halse KG; Damm P; Lindegaard ML; Amer-Wåhlin I; Hertel S; Johansen M; Mathiesen ER; Nielsen LB; Goetze JP Biomark Med; 2013 Feb; 7(1):139-46. PubMed ID: 23387495 [TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. Gegenhuber A; Struck J; Dieplinger B; Poelz W; Pacher R; Morgenthaler NG; Bergmann A; Haltmayer M; Mueller T J Card Fail; 2007 Feb; 13(1):42-9. PubMed ID: 17339002 [TBL] [Abstract][Full Text] [Related]
10. Multiple endothelial biomarkers and noninvasive vascular function in the general population: the Gutenberg Health Study. Schnabel RB; Wild PS; Schulz A; Zeller T; Sinning CR; Wilde S; Kunde J; Lubos E; Lackner KJ; Warnholtz A; Gori T; Blankenberg S; Munzel T; Hypertension; 2012 Aug; 60(2):288-95. PubMed ID: 22689741 [TBL] [Abstract][Full Text] [Related]
11. Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD. Fatemi S; Acosta S; Gottsäter A; Melander O; Engström G; Dakhel A; Zarrouk M Biomarkers; 2019 Sep; 24(6):615-621. PubMed ID: 31215249 [No Abstract] [Full Text] [Related]
13. Prognostic value of different biomarkers for cardiovascular death in unselected older patients in the emergency department. Bahrmann P; Christ M; Hofner B; Bahrmann A; Achenbach S; Sieber CC; Bertsch T Eur Heart J Acute Cardiovasc Care; 2016 Dec; 5(8):568-578. PubMed ID: 26483565 [TBL] [Abstract][Full Text] [Related]
14. Cardiovascular and inflammatory biomarkers to predict short- and long-term survival in community-acquired pneumonia: Results from the German Competence Network, CAPNETZ. Krüger S; Ewig S; Giersdorf S; Hartmann O; Suttorp N; Welte T; Am J Respir Crit Care Med; 2010 Dec; 182(11):1426-34. PubMed ID: 20639437 [TBL] [Abstract][Full Text] [Related]
15. Midregional pro-adrenomedullin and copeptin: exercise kinetics and association with the cardiopulmonary exercise response in comparison to B-type natriuretic peptide. Zurek M; Maeder MT; Brutsche MH; Lüthi A; Twerenbold R; Freese M; Rickli H; Mueller C Eur J Appl Physiol; 2014 Apr; 114(4):815-24. PubMed ID: 24390725 [TBL] [Abstract][Full Text] [Related]
16. MR-proANP and MR-proADM for risk stratification of patients with acute chest pain. Tzikas S; Keller T; Ojeda FM; Zeller T; Wild PS; Lubos E; Kunde J; Baldus S; Bickel C; Lackner KJ; Münzel TF; Blankenberg S Heart; 2013 Mar; 99(6):388-95. PubMed ID: 23213173 [TBL] [Abstract][Full Text] [Related]
17. Effectiveness of Copeptin, MR-proADM and MR-proANP in Predicting Adverse Outcomes, Alone and in Combination with Traditional Severity Scores, a Secondary Analysis in COVID-19 Patients Requiring Intensive Care Admission. Varaldo E; Rumbolo F; Prencipe N; Bioletto F; Settanni F; Mengozzi G; Grottoli S; Ghigo E; Brazzi L; Montrucchio G; Berton AM J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610784 [No Abstract] [Full Text] [Related]